About Us
In a field where time is of the essence and median brain cancer survivals post diagnosis are barely over a year, Reglagene's commitment to finding effective treatments shines through.
While many shy away from tackling brain diseases due to the complexities of developing therapies that effectively penetrate the brain, the Reglagene team wholeheartedly embraces this challenge. Their core expertise lies in the design and development of brain-penetrant medicines specifically engineered to cross the blood-brain barrier, allowing them to confront these diseases head-on.
Visionaries Unite to Transform Brain Cancer Treatment
In November 2016, the catalyst for Reglagene's inception emerged when Dr. Richard Austin (formerly of Sanofi and GSK), engaged in a transformative discussion with Dr. Laurence Hurley and Dr. Vijay Gokhale, distinguished faculty members at the University of Arizona, who shared groundbreaking insights into new methods to treat brain cancer. At this meeting, they discussed how no significant therapies have been developed for the deadliest brain cancers since 1999. Fueled by this meeting of brilliant minds, Drs. Austin, Hurley, and Gokhale joined forces, founding Reglagene and promising to develop a better solution for patients afflicted with primary and secondary brain tumors.
Redefining Drug Development with Precision and Collaboration
Throughout the ensuing years, Reglagene has fervently cultivated a powerful drug development engine. Dr. Austin began by recruiting a team of exceptional individuals who run through brick walls to ensure a new therapy would be brought to patients. This team has ingeniously intertwined its internal R&D capabilities with the expertise of renowned global service providers and esteemed academic partners. This synergy has allowed them to lay the groundwork for an agile and scalable drug development engine that initially focused on cancer therapies and has now extended its reach to encompass the treatment of diseases triggered by brain inflammation.
Breaking Boundaries. Offering Hope.
Reglagene's unwavering commitment to innovation, bolstered by their dynamic collaboration model, positions them at the forefront of the industry. The Reglagene team is dedicated to propelling the boundaries of medical science, improving the lives of patients, and making profound contributions to the field of brain cancer and brain inflammation. Of utmost importance, Reglagene aims to offer a glimmer of hope to patients battling brain cancers and other brain diseases.
To this day, the Reglagene team continues to wield their expertise in the design and development of brain-penetrant medicines to create breakthrough therapies for the safe and effective treatment of brain diseases. Their first medicine is poised to enter human clinical trials in the first half of 2025.
Meet the Team
Management
“It’s a great honor to lead a team of incredibly talented individuals who share the vision of developing next-generation cancer medicines. It’s never easy to bring ideas from concept into the clinic. But with the right team, a lot of perseverance, and taking a leap into something once thought impossible, you can change the world.” —Richard Austin, Chief Executive Officer
Richard Austin, PhD, MBA
Chief Executive Officer/President
Vijay Gokhale, PhD
Vice President of Discovery
Teri Suzuki, PhD
Vice President of
Preclinical Biology
Michael Abrahamson, PharmD
Director of Operations
Board
Reglagene's board blends pharmaceutical industry professionals with track records of delivering drug development programs and operations management with scientist–managers possessing a full command of the technology and its applications.
Lawrence Kinet, MBA
Board Chair
Laurence Hurley, PhD
Director
Chief Scientific Officer
Sharon Ayd, PhD, MBA
Director
Richard Austin, PhD, MBA
Director
CEO/President
Jeffrey Lang
Director
Advisors
Reglagene is advised by drug discovery and development professionals with exceptional track records of advancing new cancer medicines into the clinic and onto the market
Mark Chapman, PhD
Jim Heddles
Sudhir Manda, MD, FACP